HALO vs. ABBV
Compare and contrast key facts about Halozyme Therapeutics, Inc. (HALO) and AbbVie Inc. (ABBV).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: HALO or ABBV.
Key characteristics
| HALO | ABBV | |
|---|---|---|
| YTD Return | 40.07% | 24.78% |
| 1Y Return | 47.24% | 32.24% |
| 3Y Return (Ann) | 10.08% | 24.33% |
| 5Y Return (Ann) | 27.93% | 24.44% |
| 10Y Return (Ann) | 18.98% | 16.74% |
| Sharpe Ratio | 1.19 | 1.75 |
| Sortino Ratio | 1.82 | 2.28 |
| Omega Ratio | 1.24 | 1.32 |
| Calmar Ratio | 1.02 | 2.07 |
| Martin Ratio | 5.17 | 6.56 |
| Ulcer Index | 8.62% | 5.01% |
| Daily Std Dev | 37.66% | 18.85% |
| Max Drawdown | -74.26% | -45.09% |
| Current Drawdown | -19.64% | -5.67% |
Fundamentals
| HALO | ABBV | |
|---|---|---|
| Market Cap | $6.56B | $329.49B |
| EPS | $2.58 | $2.98 |
| PE Ratio | 20.07 | 62.60 |
| PEG Ratio | -2.50 | 0.44 |
| Total Revenue (TTM) | $657.27M | $41.07B |
| Gross Profit (TTM) | $501.51M | $32.43B |
| EBITDA (TTM) | $375.07M | $14.33B |
Correlation
The correlation between HALO and ABBV is 0.34, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
HALO vs. ABBV - Performance Comparison
In the year-to-date period, HALO achieves a 40.07% return, which is significantly higher than ABBV's 24.78% return. Over the past 10 years, HALO has outperformed ABBV with an annualized return of 18.98%, while ABBV has yielded a comparatively lower 16.74% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
HALO vs. ABBV - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Halozyme Therapeutics, Inc. (HALO) and AbbVie Inc. (ABBV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
HALO vs. ABBV - Dividend Comparison
HALO has not paid dividends to shareholders, while ABBV's dividend yield for the trailing twelve months is around 3.32%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
HALO Halozyme Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ABBV AbbVie Inc. | 3.32% | 3.82% | 3.49% | 3.84% | 4.41% | 4.83% | 3.89% | 2.65% | 3.64% | 3.41% | 2.54% | 3.03% |
Drawdowns
HALO vs. ABBV - Drawdown Comparison
The maximum HALO drawdown since its inception was -74.26%, which is greater than ABBV's maximum drawdown of -45.09%. Use the drawdown chart below to compare losses from any high point for HALO and ABBV. For additional features, visit the drawdowns tool.
Volatility
HALO vs. ABBV - Volatility Comparison
Halozyme Therapeutics, Inc. (HALO) has a higher volatility of 14.36% compared to AbbVie Inc. (ABBV) at 3.58%. This indicates that HALO's price experiences larger fluctuations and is considered to be riskier than ABBV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
HALO vs. ABBV - Financials Comparison
This section allows you to compare key financial metrics between Halozyme Therapeutics, Inc. and AbbVie Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities